Clinical trials: NASH (Non-Alcoholic Steatohepatitis)
Obesity, Morbid, Obesity
Omega-3 vs Very Low Calorie Diet for Liver Size Reduction
A recent review demonstrated that Non-alcoholic fatty liver disease (NAFLD) affects 10-35% of the adult population worldwide, with the prevalence approaching 85-100% in obese populations.
- Conditions
- Obesity, Morbid, Obesity, NAFLD, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT03132662
- Testing
- Omega-3, Very Low Calorie Diet
- Volunteers
- 60 people
- Sponsor
- McMaster University
Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss
Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults
Non-alcoholic fatty liver disease (NAFLD) is defined by presence of hepatic steatosis (fat accumulation in liver cells), either by imaging or by biopsy and absence of causes for secondary hepatic fat accumulation such as…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Weight Loss, Non-alcoholic Steatohepatitis (NASH)
- Trial name
- CGH-LiNASH (NCT02654665)
- Testing
- Lifestyle modification, Liraglutide
- Where
- Singapore
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
NASH - Nonalcoholic Steatohepatitis
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of itraconazole or rifampin on the pharmacokinetics and safety of EDP-305 in healthy human…
- Trial name
- NCT03213145
- Testing
- intraconazole, Rifampin, EDP 305
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of the metabolic syndrome. NAFLD is a pathologic condition which involves both hepatic steatosis and non alcoholic steatohepatitis (NASH), as…
- Trial name
- NCT01894438
- Testing
- Mediterranean lifestyle, Mediterranean Diet
- Where
- Greece
- Volunteers
- 63 people
- Sponsor
- Harokopio University
Non-alcoholic Steatohepatitis (NASH)
Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D
Test the efficacy of vitamin D to improve non-alcoholic steatohepatitis with regard to biochemical and histological parameters. Trial with medicinal product
- Trial name
- NCT01571063
- Testing
- Vitamin D3
- Where
- 2 sites in Switzerland
- Volunteers
- 22 people
- Sponsor
- University of Zurich
NAFLD, Non Alcoholic Steatohepatitis (NASH)
DHA and Vitamin D in Children With Biopsy-proven NAFLD
Non-alcoholic fatty liver disease (NAFLD) has reached epidemic proportions and is rapidly becoming the one of most common causes of chronic liver disease in children.
- Trial name
- VitD_DHA (NCT02098317)
- Testing
- DHA plus Vitamin D
- Where
- Italy
- Volunteers
- 66 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Non-Alcoholic Steatohepatitis (NASH)
Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
The primary objective of this study is to characterize the safety, tolerability and dose-limiting toxicities (DLTs) for GR-MD-02 when administered intravenously to subjects with biopsy-proven NASH with advanced liver fibrosis.
- Trial name
- NCT01899859
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Galectin Therapeutics Inc.
•Non-alcoholic Steatohepatitis (NASH)
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
NAFLD (Non-alcoholic fatty liver disease) has become the most common cause of liver disease in Western countries (hepatic manifestation of insulin resistance); NAFLD represents a cardiovascular risk factor; Lifestyle…
- Trial name
- NCT01950884
- Testing
- Ezetimibe, Lifestyle
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University of Palermo
Nonalcoholic Steatohepatitis (NASH), Hepatic Steatosis
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
The current pilot study assesses the use of magnetic resonance imaging (MRI) to quantify hepatic steatosis. It will provide preliminary data regarding the use of omega-3 fatty acid supplementation (Lovaza) for the treatment of…
- Trial name
- NCT00845845
- Testing
- Omega-3-acid ethyl esters (Lovaza)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Illinois Chicago
Nonalcoholic Steatohepatitis (NASH)
Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease
This study will evaluate the association of non-alcoholic fatty liver disease and coronary artery disease. All patients presenting for coronary angiogram will receive the following examination: Transient Elastography and…
- Trial name
- NCT01638832
- Testing
- Transient Elastography (FibroScan), Echosens, Paris, France, Controlled Attenuation Parameter (CAP), Echosens, Paris, France
- Where
- Germany
- Volunteers
- 572 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Non-Alcoholic Steatohepatitis(NASH)
Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity.
- Trial name
- NCT00706537
- Testing
- Active treatment
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Pfizer